XiVE® CAD/CAM Bridges (Abutment-supported/ Implant-supported)
NCT ID: NCT01522365
Last Updated: 2022-09-13
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
20 participants
INTERVENTIONAL
2010-10-07
2017-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Investigation on Zirconia-ceramic Three-unit Bridges With CAD-on Veneering
NCT02175329
Comparison of Two Implant Prosthetic Pathways
NCT02905838
Zirconia Bars for Mandibular Implant Overdentures
NCT06471881
Evaluation of the Prevalence and Risk Factors for Patients With Peri-implant Disease
NCT02676661
Comparison of Synthetic Bone Substitute and a Bovine-derived Xenograft in Horizontal Bone Augmentation
NCT00901017
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Treatment A: The XiVE® CAD/CAM supra-structure is fixed on abutments. The effect of platform-switching which is discussed intensely in the scientific literature is used in order to shift away the connection between implant and supra-construction (interface) from the implant edge and peri-implant tissue and towards the implant centre. However, the implant-abutment-connection area is a potential entry port for micro-organisms which have direct influence on the state of the peri-implant hard and soft tissue and consequently on the long-term prosthetic and implant success \[8\]. By using an abutment as a connector between implant and supra-structure implies the generation of one more micro-gap (between supra-structure and abutment) and possible retention of microbial plaque though located above the hard tissue level.
Treatment B: The XiVE® CAD/CAM supra-structure is fixed directly on the implants. In contrary to treatment A, only one entry port (micro-gap) for micro-organisms exists: The interface between supra-construction and implant. So, there is one main point where the initial force has main influence on the implant and the peri-implant tissue \[8-10\]. Besides, this interface lies directly on the implant shoulder level and by that on the osseous level. There is no displacement of the transitional area to the implant centre.
This study has been designed in order to collect data with regards to the CAD/CAM system used on the DENTSPLY Friadent implant system XiVE®. In particular, the peri-implant tissue outcome of abutment-supported restoration and direct implant-fixed restoration will be evaluated. Therefore a small group of subjects with partly edentulous jaw is selected to show that both techniques are efficient and safe and to demonstrate the non-inferiority with regards to the peri-implant tissue outcome for any of both techniques.
Each subject will receive both treatments, treatment A on the one site of the maxilla and treatment B on the other. The randomization method which finally defines which subject receives one treatment on the left maxilla region and the other on the right maxilla area or vice versa is described in section 5.1.
In conclusion, both treatments might have pros and cons which may affect the peri-implant tissue outcome.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Abutment-supported XiVE CAD/CAM bridge
After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed on an abutment.
Abutment-supported XiVE CAD/CAM bridge
One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
Implant-supported XiVE CAD/CAM bridge
After randomization one side of the jaw will be provided with a XiVE CAD/CAM bridge placed directly on an implant.
Implant-supported XiVE CAD/CAM bridge
One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Abutment-supported XiVE CAD/CAM bridge
One side will be provided with a XiVE CAD/CAM bridge placed directly on an abutment
Implant-supported XiVE CAD/CAM bridge
One side will be provided with a XiVE CAD/CAM bridge fixed directly on the implant
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Female subject of child-bearing potential must use reliable methods of contraception.
3. Subject has partly edentulous maxilla (free-end or large gap in posterior area on both sides).
4. For all implants immobility and clear percussion sound is applicable.
5. The subject is healthy and compliant with good oral hygiene.
6. Favorable and stable occlusal relationship between the remaining teeth.
7. Subject must be reliable, cooperative, and in the opinion of the Investigator, likely to be compliant with study procedures.
8. Subject provides written informed consent signed and dated prior to entering the study.
9. Implantation of XiVE® implants at least 3 months ago.
10. XiVE® implants have been placed primary stable by considering sufficient horizontal and vertical bone dimension.
Exclusion Criteria
2. Subject with planned or performed head and neck radiation.
3. Known unavailability of subject for FU Visit(s).
4. Subject has - in the opinion of the investigator - any systemic metabolic disorder or bone disorder or is taking medication that compromises or might have compromised post-operative tissue regeneration or osseointegration.
5. Subject has major bone defects in the implantation area.
6. Subject is taking medication that compromises or might have compromised post-operative healing and/or osseointegration (e. g. bisphosphonates).
7. Subject exhibits an oral infection.
8. Subject has received any investigational drug within 30 days prior to screening.
9. Severe bruxing.
10. Subject has a clinically significant or unstable medical or physiological condition.
11. Female subject is pregnant or lactating or intends to become pregnant during the course of the study.
12. Subject is not willing to participate in the study or not able to understand the content of the study.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Dentsply Implants Manufacturing GmbH
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Manfred Wichmann, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
Erlangen University Hospital
Thomas Dietrich, Prof. Dr. Dr.
Role: PRINCIPAL_INVESTIGATOR
Birmingham University, School of Dentistry
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Birmingham, School of dentistry
Birmingham, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DF0909-1-272-1x-1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.